Organization & Developments: Aimmune

Parents

2017: Aimmune Soars On Rival Drug Flop For Peanut Allergy - Aimmune Therapeutics (NASDAQ:AIMT)
2018: Aimmune Moves One Step Closer To Helping Those With Peanut Allergy_seekingalpha.com
2018: Aimmune’s PhIII peanut allergy study wows on the primary endpoint, setting up FDA pitch
2019: Advisory Body Backs Aimmune Peanut Allergy Drug, Next Up: the FDA
2019: Aimmune: Delivering The Silver Bullets For Various Food Allergies_seekingalpha.com
2019: Aimmune: FDA Panel Nod Pushes Peanut Allergy Treatment One Step Closer To Potential Approval_seekingalpha.com
2019: Shutdown has Aimmune waiting on FDA on multiple fronts
2020: Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
2020: The Play On Aimmune Therapeutics
Aimmune is developing treatments for food allergies using biologic product candidates and characterized oral desensitization immunotherapy (CODIT™) .
Clinical-stage biopharmaceutical company
The company is focused on developing and commercializing product candidates for the treatment of peanut and other food allergies.